Association Between Adjuvant Therapy and Survival in Resected Pancreatic Ductal Adenocarcinoma After Different Types and Durations of Neoadjuvant Therapy
Patients receiving 5FU-based NAT showed improved survival compared with patients receiving gemcitabine-based NAT before surgery for PDAC. Adjuvant therapy improved survival, particularly in patients with shorter NAT duration.
Authors
- Kelly J. Lafaro (ORCID: https://orcid.org/0000-0002-7070-7269)
- Joseph R. Habib (ORCID: https://orcid.org/0000-0003-3445-2278)
- William R. Burns (ORCID: https://orcid.org/0000-0002-7634-9730)
- Brady A. Campbell (ORCID: https://orcid.org/0000-0002-0792-6928)
- Lois A. Daamen (ORCID: https://orcid.org/0000-0001-9227-7178)
- I Quintus Molenaar
- P. Andel (ORCID: https://orcid.org/0009-0006-9341-9282)
- Ammar A. Javed (ORCID: https://orcid.org/0000-0002-5463-5250)
- Jin He
- Richard A. Burkhart (ORCID: https://orcid.org/0000-0002-1618-4006)
- Christopher L. Wolfgang (ORCID: https://orcid.org/0000-0002-8717-0373)
- John L. Cameron
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- St. Antonius Ziekenhuis (NL)
- Cancer Genomics Centre (NL)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1245/s10434-025-17439-x
- Citations
- 3
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 3.14